Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management

Yoshihiro Sato; Shingo Tsujinaka; Tomoya Miura; Yoh Kitamura; Hideyuki Suzuki; Chikashi Shibata

doi:10.3390/cancers15164154

Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management

Cancers (Basel). 2023 Aug 17;15(16):4154. doi: 10.3390/cancers15164154.

Authors

Yoshihiro Sato¹, Shingo Tsujinaka¹, Tomoya Miura¹, Yoh Kitamura¹, Hideyuki Suzuki¹, Chikashi Shibata¹

Affiliation

¹ Division of Gastroenterological Surgery, Department of Surgery, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan.

Abstract

Patients with inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn's disease, have an increased risk of developing colorectal cancer (CRC). Although advancements in endoscopic imaging techniques, integrated surveillance programs, and improved medical therapies have contributed to a decreased incidence of CRC in patients with IBD, the rate of CRC remains higher in patients with IBD than in individuals without chronic colitis. Patients with IBD-related CRCs exhibit a poorer prognosis than those with sporadic CRCs, owing to their aggressive histological characteristics and lower curative resection rate. In this review, we present an updated overview of the epidemiology, etiology, risk factors, surveillance strategies, treatment recommendations, and prognosis of IBD-related CRCs.

Keywords: colorectal cancer; inflammatory bowel diseases; prognosis; surveillance.

Publication types

Review

Grants and funding

This research received no external funding.